Berotralstat
Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema[1][2].
Product Specifications
CAS Number
1809010-50-1
Product Name Alternative
BCX7353
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Kallikrein
Type
Reference compound
Related Pathways
Immunology/Inflammation
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/berotralstat.html
Purity
99.70
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(C(F)(F)F)=NN1C2=CC(CN)=CC=C2)NC3=CC([C@@H](C4=CC(C#N)=CC=C4)NCC5CC5)=CC=C3F
Molecular Formula
C30H26F4N6O
Molecular Weight
562.56
Precautions
H315, H319, H320
References & Citations
[1]Zuraw B, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. J Allergy Clin Immunol. 2020; S0091-6749 (20) 31484-6.|[2]Richard E. Kast, et al. Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma. Neuroglia. 2024, 5 (3), 223-233.|[3]Perego F, et al., Current and emerging biologics for the treatment of hereditary angioedema. Expert Opin Biol Ther. 2019 Jun;19 (6) :517-526.|[4]Wan J, et al., Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood. Blood Adv. 2024 Jun 25;8 (12) :3045-3057.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LV687550 1.0 µg DNA
Spink3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
Sign In for Pricing
View Details